Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.

ABSTRACT:

Background

Currently biomarkers play an essential role in diagnosis, treatment, and management of cancer. In non-small cell lung cancer (NSCLC) determination of biomarkers such as ALK, EGFR, ROS1 or PD-L1 is mandatory for an adequate treatment decision. The aim of this study is to determine the clinical and economic impact of current anaplastic lymphoma kinase testing scenario in Spain.

Methods

A joint model, composed by decision-tree and Markov models, was developed to estimate the long-term health outcomes and costs of NSCLC patients, by comparing the current testing scenario for ALK in Spain vs a hypothetical no-testing. The current distribution of testing strategies for ALK determination and their sensitivity and specificity data were obtained from the literature. Treatm

SUBMITTER: Nadal E 

PROVIDER: S-EPMC8194132 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature